Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Potential new Alzheimer's drugs advancing in clinical trials

08.04.2010
After years of preparation and anticipation, scientists who discover and develop new medications are about to answer a key question about Alzheimer's disease: Will drugs that block formation of abnormal clumps of protein in the brain called amyloid-beta slow the progression of the devastating disease?

The cover story in the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine, assesses the scientific foundation and clinical landscape of those amyloid-beta blockers.

C&EN Senior Editor Lisa Jarvis notes that amyloid-beta is at the heart of a central hypothesis — and simmering controversy — about Alzheimer's disease. Some scientists are convinced that amyloid-beta is the root cause of the nerve-cell death and subsequent mental decline in individuals with Alzheimer's disease.

Others think that something else, perhaps a still-unidentified environmental neurotoxin, is the real culprit. That mystery agent, they suspect, triggers formation of beta-amyloid.

If the clinical trials are successful, doctors within 5-10 years could have an arsenal of new drugs that can slow the progression of Alzheimer's. If the trials fail, its back to the drawing board to find new hypothesis and drug targets for the disease, the article notes.

Michael Bernstein | EurekAlert!
Further information:
http://www.acs.org

More articles from Life Sciences:

nachricht Protein expression gets the heart pumping
22.04.2014 | Baylor College of Medicine

nachricht Cow manure harbors diverse new antibiotic resistance genes
22.04.2014 | American Society for Microbiology

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Fachtagung: Dienstleistung in der digitalen Gesellschaft

22.04.2014 | Veranstaltungen

Was kann Stuttgart 21 von Zürich lernen?

22.04.2014 | Veranstaltungen

Vitamin D: Neue Hoffnung für Krebspatienten?

22.04.2014 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Stellar Datenrettung erweitert Partnerprogramm für die DACH Region - Partnerkonzept für Österreich startet im April

22.04.2014 | Unternehmensmeldung

JULABO gewinnt JOBMOTOR 2013

22.04.2014 | Unternehmensmeldung

Diversifizierte Unternehmen und Conglomerate Discount – zwei Seiten einer Medaille?

22.04.2014 | Wirtschaft Finanzen